.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Argus Health
Colorcon
UBS
Harvard Business School
Cerilliant
Mallinckrodt
Daiichi Sankyo
Cantor Fitzgerald
Baxter

Generated: September 25, 2017

DrugPatentWatch Database Preview

TEVETEN Drug Profile

« Back to Dashboard

Which patents cover Teveten, and when can generic versions of Teveten launch?

Teveten is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for Tradename: TEVETEN

Patents:0
Applicants:1
NDAs:2
Bulk Api Vendors: see list82
Clinical Trials: see list1
Patent Applications: see list768
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TEVETEN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-004Dec 22, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-001Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-005Dec 22, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-006May 27, 1999ABRXYesYes► Subscribe► Subscribe► Subscribe
Abbvie
TEVETEN HCT
eprosartan mesylate; hydrochlorothiazide
TABLET;ORAL021268-002Nov 1, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TEVETEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-004Dec 22, 1997► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-005Dec 22, 1997► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-005Dec 22, 1997► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-006May 27, 1999► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-004Dec 22, 1997► Subscribe► Subscribe
Abbvie
TEVETEN
eprosartan mesylate
TABLET;ORAL020738-006May 27, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for TEVETEN

Drugname Dosage Strength RLD Submissiondate
eprosartan mesylateTablets400 mg and 600 mgTeveten5/10/2010
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
Cantor Fitzgerald
US Department of Justice
Mallinckrodt
Fish and Richardson
Deloitte
Covington
Citi
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot